HK1246689A1 - 溴莫尼定和噻嗎洛爾的固定劑量組合 - Google Patents
溴莫尼定和噻嗎洛爾的固定劑量組合Info
- Publication number
- HK1246689A1 HK1246689A1 HK18106462.6A HK18106462A HK1246689A1 HK 1246689 A1 HK1246689 A1 HK 1246689A1 HK 18106462 A HK18106462 A HK 18106462A HK 1246689 A1 HK1246689 A1 HK 1246689A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bromonidine
- timolol
- fixed dose
- dose combination
- combination
- Prior art date
Links
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 title 1
- 229940000425 combination drug Drugs 0.000 title 1
- 229960004605 timolol Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135320P | 2015-03-19 | 2015-03-19 | |
| PCT/US2016/022874 WO2016149498A1 (en) | 2015-03-19 | 2016-03-17 | Fixed dose combination of bromonidine and timolol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1246689A1 true HK1246689A1 (zh) | 2018-09-14 |
Family
ID=55640942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18106462.6A HK1246689A1 (zh) | 2015-03-19 | 2018-05-18 | 溴莫尼定和噻嗎洛爾的固定劑量組合 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20180078500A1 (zh) |
| EP (2) | EP4420726A3 (zh) |
| JP (3) | JP7199146B2 (zh) |
| KR (1) | KR20170129823A (zh) |
| CN (1) | CN107427460A (zh) |
| AU (3) | AU2016233125A1 (zh) |
| CA (1) | CA2977825A1 (zh) |
| HK (1) | HK1246689A1 (zh) |
| WO (1) | WO2016149498A1 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7170436B2 (ja) * | 2017-06-28 | 2022-11-14 | 千寿製薬株式会社 | 水溶性高分子を含む点眼剤 |
| WO2019112030A1 (ja) * | 2017-12-08 | 2019-06-13 | 千寿製薬株式会社 | 水溶性高分子を含む水性液剤 |
| JP7378959B2 (ja) * | 2018-05-11 | 2023-11-14 | 千寿製薬株式会社 | 眼科用組成物 |
| US20210220515A1 (en) * | 2018-05-25 | 2021-07-22 | Eyebright Medical Technology (Beijing) Co., Ltd. | Viscoelastic agent material |
| JP7630944B2 (ja) | 2019-09-12 | 2025-02-18 | 千寿製薬株式会社 | ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物 |
| GR1010024B (el) * | 2020-05-06 | 2021-06-01 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2003198C (en) * | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| CN1441679A (zh) * | 2000-07-14 | 2003-09-10 | 阿勒根公司 | 包含具有提高的溶解度的治疗活性组分的组合物 |
| PL360707A1 (en) * | 2000-07-14 | 2004-09-20 | Allergan Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
| CA2505836C (en) * | 2004-05-06 | 2013-08-27 | Alcon Inc. | Topical brimonidine tartrate formulations that lack chlorine dioxide |
| LT2522365T (lt) | 2004-11-24 | 2017-02-10 | Meda Pharmaceuticals Inc. | Kompozicijos, apimančios azelastiną, ir jų panaudojimo būdai |
| US20070238732A1 (en) * | 2006-04-10 | 2007-10-11 | Allergan, Inc. | Brimonidine and timolol compositions |
| WO2008024846A2 (en) * | 2006-08-25 | 2008-02-28 | Allergan, Inc. | Brimonidine and timolol compositions |
| WO2011087790A1 (en) * | 2009-12-22 | 2011-07-21 | Allergan, Inc. | Triple combination for lowering intraocular pres sure |
| US10213431B2 (en) * | 2010-07-29 | 2019-02-26 | Allergan, Inc. | Preservative free brimonidine and timolol solutions |
| CN103501804A (zh) | 2010-12-21 | 2014-01-08 | 雷科制药公司 | 眼泪替代物 |
| EP3086776B1 (en) * | 2013-12-24 | 2020-06-17 | Sentiss Pharma Private Limited | Topical brimonidine tartrate ophthalmic solution |
| US20160331746A1 (en) * | 2015-05-12 | 2016-11-17 | University Of South Florida | Sortilin-Binding Small Molecules for Increasing Glucose Uptake |
-
2016
- 2016-03-17 CN CN201680015524.5A patent/CN107427460A/zh active Pending
- 2016-03-17 CA CA2977825A patent/CA2977825A1/en active Pending
- 2016-03-17 KR KR1020177029678A patent/KR20170129823A/ko not_active Application Discontinuation
- 2016-03-17 EP EP24168727.6A patent/EP4420726A3/en active Pending
- 2016-03-17 EP EP16712655.6A patent/EP3270892B1/en active Active
- 2016-03-17 WO PCT/US2016/022874 patent/WO2016149498A1/en active Application Filing
- 2016-03-17 JP JP2017548997A patent/JP7199146B2/ja active Active
- 2016-03-17 AU AU2016233125A patent/AU2016233125A1/en not_active Abandoned
- 2016-03-17 US US15/558,515 patent/US20180078500A1/en not_active Abandoned
-
2018
- 2018-05-18 HK HK18106462.6A patent/HK1246689A1/zh unknown
-
2021
- 2021-03-12 JP JP2021040110A patent/JP2021102626A/ja active Pending
- 2021-06-04 AU AU2021203665A patent/AU2021203665A1/en not_active Abandoned
- 2021-12-16 US US17/644,719 patent/US20220370346A1/en active Pending
-
2023
- 2023-04-07 JP JP2023062494A patent/JP2023086773A/ja active Pending
- 2023-07-24 AU AU2023208076A patent/AU2023208076A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023086773A (ja) | 2023-06-22 |
| AU2023208076A1 (en) | 2023-08-10 |
| EP4420726A3 (en) | 2024-11-13 |
| AU2021203665A1 (en) | 2021-09-02 |
| JP2018508545A (ja) | 2018-03-29 |
| KR20170129823A (ko) | 2017-11-27 |
| US20180078500A1 (en) | 2018-03-22 |
| EP3270892A1 (en) | 2018-01-24 |
| EP3270892B1 (en) | 2024-04-10 |
| EP4420726A2 (en) | 2024-08-28 |
| CA2977825A1 (en) | 2016-09-22 |
| CN107427460A (zh) | 2017-12-01 |
| US20220370346A1 (en) | 2022-11-24 |
| JP2021102626A (ja) | 2021-07-15 |
| JP7199146B2 (ja) | 2023-01-05 |
| AU2016233125A1 (en) | 2017-09-14 |
| WO2016149498A1 (en) | 2016-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287437A (en) | Flavociclib solid dosage forms | |
| HK1247614A1 (zh) | 治療化合物及其用途 | |
| IL258931A (en) | Medicinal compounds and methods | |
| HK1258062A1 (zh) | 給予惡拉戈利的方法 | |
| HK1232137A1 (zh) | 治療化合物和組合物 | |
| IL282482A (en) | Variants of protoxin-II and methods of use | |
| ZA201902090B (en) | Combination treatments comprising administration of imidazopyrazinones | |
| HK1246689A1 (zh) | 溴莫尼定和噻嗎洛爾的固定劑量組合 | |
| HK1248697A1 (zh) | 治療化合物及其用途 | |
| IL282508A (en) | Variants of protoxin-II and methods of use | |
| IL285882A (en) | Medicinal uses for l–4–chlorokynurenine | |
| ZA201802256B (en) | Compounds and therapeutic uses thereof | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| GB201617064D0 (en) | Compounds and their therapeutic use | |
| HK1258056A1 (zh) | 治療性化合物和其使用方法 | |
| SMT201800640T1 (it) | Irisina per la cura e la prevenzione dell'osteoporosi | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| PL3341481T3 (pl) | Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition |